During the past decade, University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 3 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 3 trials as a collaborator, "National Institutes of Health (NIH)" with 3 trials as a collaborator, "International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)" with 2 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator and "Copenhagen HIV Programme" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases" are "COVID-19" (3 trials), "COVID" (1 trials), "Clostridium Difficile" (1 trials), "Influenza" (1 trials) and "Influenza and Other Novel Respiratory Viruses" (1 trials). Many other conditions were trialed in "University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases" in a lesser frequency.

Most popular intervention types in "University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases" are "Drug" (3 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Remdesivir" (3 trials), "Baricitinib" (1 trials) and "Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases" are 6 trials for "All" genders.

Currently, there are NaN active trials in "University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".